01403nas a2200205   4500000000100000008004100001653001200042653001200054653002100066100001800087700001600105700001400121700001500135700001500150245005500165856026000220300001000480490000600490520070100496       2018                            d10aleprosy10aDapsone10aSulfone Syndrome1 aGonçalves TS1 aPereira ECG1 aNetto PRS1 aFreire RAC1 aMendes SUR00a[Case report: Sulfone Syndrome in leprosy patient]  uhttp://scholar.google.nl/scholar_url?url=https://sistemas.uft.edu.br/periodicos/index.php/patologia/article/download/5071/14513&hl=nl&sa=X&d=13403405165673474039&scisig=AAGBfm2P00zIuSxYRbZTyyMswQqxytX2aA&nossl=1&oi=scholaralrt&hist=732gnZIAAAAJ:1269093288  a28-310 v53 a<p>We report the case of a woman with leprosy who was treated with MDT-MB/ WHO and presented 4 weeks after the start of treatment, fever, malaise, weakness, jaundice, edema and rashes in feet and hands, hepatitis, pruritus, dysphagia, haemolytic anemia, submandibular lymph node, as well as nausea, vomiting and epigastric pain. Laboratory tests showed decreased hemoglobin, leukocytosis, eosinophilia, increased hepatic transaminases, indirect hyperbilirubinemia, hypoalbuminemia, DHL and elevated TAP. A diagnosis of Dapsone Syndrome was established, treatment of leprosy was suspended and the patient was advised to return treatment after hospital discharge, with replacement of dapsone.</p>